7T Brain MRS in HIV Infection: Correlation with Cognitive Impairment and Performance on Neuropsychological Tests

References

1. 1.↵
   2. Gandhi NS,
   3. Skolasky RL,
   4. Peters KB, et al

   . A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. J Neurovirol 2011;17:159–65 doi:10.1007/s13365-011-0023-8 pmid:21437751

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Kakinami L,
   3. de Bruyn G,
   4. Pronyk P, et al

   . The impact of highly active antiretroviral therapy on activities of daily living in HIV-infected adults in South Africa. AIDS Behav 2011;15:823–31 doi:10.1007/s10461-010-9776-y pmid:20703794

   CrossRefPubMed
3. 3.↵
   2. Schifitto G,
   3. Kieburtz K,
   4. McDermott MP, et al

   . Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology 2001;56:415–18 doi:10.1212/WNL.56.3.415 pmid:11171916

   Abstract/FREE Full Text
4. 4.↵
   2. Vivithanaporn P,
   3. Heo G,
   4. Gamble J, et al

   . Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology 2010;75:1150–58 doi:10.1212/WNL.0b013e3181f4d5bb pmid:20739646

   Abstract/FREE Full Text
5. 5.↵
   2. Sailasuta N,
   3. Ross W,
   4. Ananworanich J, et al

   ; RV254/SEARCH 010 protocol teams. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One 2012;7:e49272 doi:10.1371/journal.pone.0049272 pmid:23229129

   CrossRefPubMed
6. 6.↵
   2. Lentz MR,
   3. Degaonkar M,
   4. Mohamed MA, et al

   . Exploring the relationship of macrophage colony-stimulating factor levels on neuroaxonal metabolism and cognition during chronic human immunodeficiency virus infection. J Neurovirol 2010;16:368–76 doi:10.3109/13550284.2010.513029 pmid:20839921

   CrossRefPubMed
7. 7.↵
   2. Letendre S,
   3. Marquie-Beck J,
   4. Capparelli E, et al

   ; CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65–70 doi:10.1001/archneurol.2007.31 pmid:18195140

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Clifford DB

   . HIV-associated neurocognitive disorder. Curr Opin Infect Dis 2017;30:117–22 doi:10.1097/QCO.0000000000000328 pmid:27798498

   CrossRefPubMed
9. 9.↵
   2. Tozzi V,
   3. Balestra P,
   4. Bellagamba R, et al

   . Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007;45:174–82 doi:10.1097/QAI.0b013e318042e1ee pmid:17356465

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Harezlak J,
    3. Buchthal S,
    4. Taylor M, et al

    ; HIV Neuroimaging Consortium. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011;25:625–33 doi:10.1097/QAD.0b013e3283427da7 pmid:21297425

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Neuenburg JK,
    3. Brodt HR,
    4. Herndier BG, et al

    . HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31:171–77 doi:10.1097/00126334-200210010-00007 pmid:12394795

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Valcour V,
    3. Paul R,
    4. Neuhaus J, et al

    . The effects of age and HIV on neuropsychological performance. J Int Neuropsychol Soc 2011;17:190–95 doi:10.1017/S1355617710001438 pmid:21144102

    CrossRefPubMed
13. 13.↵
    2. Valcour V,
    3. Shikuma C,
    4. Shiramizu B, et al

    . Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004;63:822–27 doi:10.1212/01.WNL.0000134665.58343.8D pmid:15365130

    Abstract/FREE Full Text
14. 14.↵
    2. Van Zijl PC,
    3. Barker PB

    . Magnetic resonance spectroscopy and spectroscopic imaging for the study of brain metabolism. Ann N Y Acad Sci 1997;820:75–96 doi:10.1111/j.1749-6632.1997.tb46190.x pmid:9237450

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Chong WK,
    3. Sweeney B,
    4. Wilkinson ID, et al

    . Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. Radiology 1993;188:119–24 doi:10.1148/radiology.188.1.8099750 pmid:8099750

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Chang L,
    3. Ernst T,
    4. Leonido-Yee M, et al

    . Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 1999;53:782–89 doi:10.1212/WNL.53.4.782 pmid:10489041

    Abstract/FREE Full Text
17. 17.↵
    2. Ernst T,
    3. Jiang CS,
    4. Nakama H, et al

    . Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder. J Magn Reson Imaging 2010;32:1045–53 doi:10.1002/jmri.22366 pmid:21031507

    CrossRefPubMed
18. 18.↵
    2. Mohamed MA,
    3. Barker PB,
    4. Skolasky RL, et al

    . Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Mag Reson Imaging 2010;28:1251–57 doi:10.1016/j.mri.2010.06.007 pmid:20688449

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Sailasuta N,
    3. Shriner K,
    4. Ross B

    . Evidence of reduced glutamate in the frontal lobe of HIV-seropositive patients. NMR Biomed 2009;22:326–31 doi:10.1002/nbm.1329 pmid:18988228

    CrossRefPubMed
20. 20.↵
    2. Menon DK,
    3. Ainsworth JG,
    4. Cox IJ, et al

    . Proton MR spectroscopy of the brain in AIDS dementia complex. J Comput Assist Tomogr 1992;16:538–42 doi:10.1097/00004728-199207000-00007 pmid:1629410

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Meyerhoff DJ,
    3. MacKay S,
    4. Poole N, et al

    . N-acetylaspartate reductions measured by 1H MRSI in cognitively impaired HIV-seropositive individuals. Magn Reson Imaging 1994;12:653–59 doi:10.1016/0730-725X(94)92460-0 pmid:8057770

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Barker PB,
    3. Lee RR,
    4. McArthur JC

    . AIDS dementia complex: evaluation with proton MR spectroscopic imaging. Radiology 1995;195:58–64 doi:10.1148/radiology.195.1.7892496 pmid:7892496

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Laubenberger J,
    3. Häussinger D,
    4. Bayer S, et al

    . HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times. Radiology 1996;199:805–10 doi:10.1148/radiology.199.3.8638009 pmid:8638009

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Navia BA,
    3. Rostasy K

    . The AIDS dementia complex: clinical and basic neuroscience with implications for novel molecular therapies. Neurotox Res 2005;8:3–24 doi:10.1007/BF03033817 pmid:16260383

    CrossRefPubMed
25. 25.↵
    2. Paul RH,
    3. Yiannoutsos CT,
    4. Miller EN, et al

    . Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci 2007;19:283–92 doi:10.1176/jnp.2007.19.3.283 pmid:17827413

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Barker PB,
    3. Hearshen DO,
    4. Boska MD

    . Single-voxel proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med 2001;45:765–69 doi:10.1002/mrm.1104 pmid:11323802

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Chang L,
    3. Ernst T,
    4. St Hillaire C, et al

    . Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther 2004;9:431–40 pmid:15259906

    PubMedWeb of Science
28. 28.↵
    2. Young AC,
    3. Yiannoutsos CT,
    4. Hegde M, et al

    . Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection. Neurology 2014;83:1592–600 doi:10.1212/WNL.0000000000000932 pmid:25261502

    Abstract/FREE Full Text
29. 29.↵
    2. Tkác I,
    3. Oz G,
    4. Adriany G, et al

    . In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med 2009;62:868–79 doi:10.1002/mrm.22086 pmid:19591201

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Stephenson MC,
    3. Gunner F,
    4. Napolitano A, et al

    . Applications of multi-nuclear magnetic resonance spectroscopy at 7T. World J Radiol 2011;3:105–13 doi:10.4329/wjr.v3.i4.105 pmid:21532871

    CrossRefPubMed
31. 31.↵
    2. Antinori A,
    3. Arendt G,
    4. Becker JT, et al

    . Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789–99 doi:10.1212/01.WNL.0000287431.88658.8b pmid:17914061

    Abstract/FREE Full Text
32. 32.↵
    2. Radloff LS

    . The use of the Center for Epidemiologic Studies Depression Scale in adolescents and young adults. J Youth Adolesc 1991;20:149–66 doi:10.1007/BF01537606 pmid:24265004

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Giebel CM,
    3. Challis D,
    4. Montaldi D

    . The newly revised interview for deteriorations in daily living activities in dementia (R-IDDD2): distinguishing initiative from performance at assessment. Int Psychogeriatr 2017;29:497–507 doi:10.1017/S1041610216002003 pmid:27890028

    CrossRefPubMed
34. 34.↵
    2. Kaur N,
    3. Belchior P,
    4. Gelinas I, et al

    . Critical appraisal of questionnaires to assess functional impairment in individuals with mild cognitive impairment. Int Psychogeriatr 2016;28:1425–39 doi:10.1017/S104161021600017X pmid:27072886

    CrossRefPubMed
35. 35.↵
    2. Fantoni M,
    3. Izzi I,
    4. Del Borgo C, et al

    . Inter-rater reliability of a modified Karnofsky Scale of Performance Status for HIV-infected individuals. AIDS Patient Care STDS 1999;13:23–28 doi:10.1089/apc.1999.13.23 pmid:11362083

    CrossRefPubMed
36. 36.↵
    2. Gaines JJ,
    3. Shapiro A,
    4. Alt M, et al

    . Semantic clustering indexes for the Hopkins Verbal Learning Test-Revised: initial exploration in elder control and dementia groups. Appl Neuropsychol 2006;13:213–22 doi:10.1207/s15324826an1304_2 pmid:17362141

    CrossRefPubMed
37. 37.↵
    2. Shapiro AM,
    3. Benedict RH,
    4. Schretlen D, et al

    . Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol 1999;13:348–58 doi:10.1076/clin.13.3.348.1749 pmid:10726605

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Woods SP,
    3. Scott JC,
    4. Conover E, et al

    ; HIV Neurobehavioral Research Center Group. Test-retest reliability of component process variables within the Hopkins Verbal Learning Test-Revised. Assessment 2005;12:96–100 doi:10.1177/1073191104270342 pmid:15695747

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Chang L,
    3. Lee PL,
    4. Yiannoutsos CT, et al

    ; HIV MRS Consortium. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage 2004;23:1336–47 doi:10.1016/j.neuroimage.2004.07.067 pmid:15589098

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Fjell AM,
    3. McEvoy L,
    4. Holland D, et al

    ; Alzheimer's Disease Neuroimaging Initiative. What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog Neurobiol 2014;117:20–40 doi:10.1016/j.pneurobio.2014.02.004 pmid:24548606

    CrossRefPubMed
41. 41.↵
    2. Driscoll I,
    3. Troncoso JC,
    4. Rudow G, et al

    . Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol 2012;124:823–31 doi:10.1007/s00401-012-1025-1 pmid:22864813

    CrossRefPubMedWeb of Science
42. 42.↵
    2. Öz G,
    3. Tkáč I

    . Short-echo, single-shot, full-intensity 1H MRS for neurochemical profiling at 4T: validation in the cerebellum and brainstem. Magn Reson Med 2011;65:901–10 doi:10.1002/mrm.22708 pmid:21413056

    CrossRefPubMed
43. 43.↵
    2. Pradhan S,
    3. Bonekamp S,
    4. Gillen JS, et al

    . Comparison of single voxel brain MRS at 3T and 7T using 32-channel head coils. Magn Reson Imaging 2015;33:1013–18 doi:10.1016/j.mri.2015.06.003 pmid:26117693

    CrossRefPubMed
44. 44.↵
    2. Provencher SW

    . Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672–79 doi:10.1002/mrm.1910300604 pmid:8139448

    CrossRefPubMedWeb of Science
45. 45.↵
    2. Wilkinson ID,
    3. Miller RF,
    4. Miszkiel KA, et al

    . Cerebral proton magnetic resonance spectroscopy in asymptomatic HIV infection. AIDS 1997;11:289–95 doi:10.1097/00002030-199703110-00005 pmid:9147419

    CrossRefPubMed
46. 46.↵
    2. Lentz MR,
    3. Kim WK,
    4. Kim H, et al

    . Alterations in brain metabolism during the first year of HIV infection. J Neurovirol 2011;17:220–29 doi:10.1007/s13365-011-0030-9 pmid:21494901

    CrossRefPubMedWeb of Science
47. 47.↵
    2. McArthur JC,
    3. Steiner J,
    4. Sacktor N, et al

    . Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010;67:699–714 doi:10.1002/ana.22053 pmid:20517932

    CrossRefPubMedWeb of Science
48. 48.↵
    2. Cloak CC,
    3. Chang L,
    4. Ernst T

    . Increased frontal white matter diffusion is associated with glial metabolites and psychomotor slowing in HIV. J Neuroimmunol 2004;157:147–52 doi:10.1016/j.jneuroim.2004.08.043 pmid:15579292

    CrossRefPubMedWeb of Science
49. 49.↵
    2. Mohamed MA,
    3. Lentz MR,
    4. Lee V, et al

    . Factor analysis of proton MR spectroscopic imaging data in HIV infection: metabolite-derived factors help identify infection and dementia. Radiology 2010;254:577–86 doi:10.1148/radiol.09081867 pmid:20093528

    CrossRefPubMedWeb of Science
50. 50.↵
    2. Chang L,
    3. Ernst T,
    4. Witt MD, et al

    . Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. Neuroimage 2002;17:1638–48 doi:10.1006/nimg.2002.1254 pmid:12414302

    CrossRefPubMedWeb of Science
51. 51.↵
    2. Wijtenburg SA,
    3. Rowland LM,
    4. Edden RA, et al

    . Reproducibility of brain spectroscopy at 7T using conventional localization and spectral editing techniques. J Magn Reson Imaging 2013;38:460–67 doi:10.1002/jmri.23997 pmid:23292856

    CrossRefPubMed
52. 52.↵
    2. Mekle R,
    3. Mlynárik V,
    4. Gambarota G, et al

    . MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med 2009;61:1279–85 doi:10.1002/mrm.21961 pmid:19319893

    CrossRefPubMed
53. 53.↵
    2. Sailasuta N,
    3. Ananworanich J,
    4. Lerdlum S, et al

    ; SEARCH 011 Study Group. Neuronal-glia markers by magnetic resonance spectroscopy in HIV before and after combination antiretroviral therapy. J Acquir Immune Defic Syndr 2016;71:24–30 doi:10.1097/QAI.0000000000000779 pmid:26258565

    CrossRefPubMed
54. 54.↵
    2. Castellano JF,
    3. Fletcher BR,
    4. Kelley-Bell B, et al

    . Age-related memory impairment is associated with disrupted multivariate epigenetic coordination in the hippocampus. PLoS One 2012;7:e33249 doi:10.1371/journal.pone.0033249 pmid:22438904

    CrossRefPubMed
55. 55.↵
    2. Castellano JF,
    3. Fletcher BR,
    4. Patzke H, et al

    . Reassessing the effects of histone deacetylase inhibitors on hippocampal memory and cognitive aging. Hippocampus 2014;24:1006–16 doi:10.1002/hipo.22286 pmid:24753063

    CrossRefPubMedWeb of Science
56. 56.↵
    2. Daugherty A,
    3. Raz N

    . Age-related differences in iron content of subcortical nuclei observed in vivo: a meta-analysis. Neuroimage 2013;70:113–21 doi:10.1016/j.neuroimage.2012.12.040 pmid:23277110

    CrossRefPubMed
57. 57.↵
    2. Haacke EM,
    3. Miao Y,
    4. Liu M, et al

    . Correlation of putative iron content as represented by changes in R2* and phase with age in deep gray matter of healthy adults. J Magn Reson Imaging 2010;32:561–76 doi:10.1002/jmri.22293 pmid:20815053

    CrossRefPubMed
58. 58.↵
    2. Persson N,
    3. Wu J,
    4. Zhang Q, et al

    . Age and sex related differences in subcortical brain iron concentrations among healthy adults. Neuroimage 2015;122:385–98 doi:10.1016/j.neuroimage.2015.07.050 pmid:26216277

    CrossRefPubMed